Tag: GlaxoSmithKline

Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

gsk-servier
GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow.

GSK received approval for Shingrix vaccine in Europe and Japan

gsk
GlaxoSmithKline announced that the European Commission has approved Shingrix for the prevention of shingles and post-herpetic neuralgia. The Japanese Ministry of Health, Labour and Welfare has also approved Shingrix.

GSK brings legal action against Gilead Sciences

gsk
ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences

Avara CDMO bought healthcare facility from GSK

api
Avara Pharmaceutical Services has signed an agreement with GSK to acquire a GSK consumer healthcare manufacturing facility

Insilico Medicine and GSK set up a collaboration focused on AI drug discovery

drug discovery
Insilico Medicine announced that it has formed a collaboration with GSK to explore how Insilico's AI capability can enhance its drug discovery process

GSK closes neuroscience R&D site in China and relocates it to USA

GlaxoSmithKline
GlaxoSmithKline is closing its neuroscience research and development site in China and is moving it to the company’s hub in the Philadelphia which includes Conshohocken and Collegeville

Exscientia and GSK started drug discovery collaboration

AI
Exscientia, an innovative company at the forefront of Artificial Intelligence-driven drug discovery, announced it has entered into a strategic drug discovery collaboration with GlaxoSmithKline

Teva lost a patent case to GSK and must pay $235 million

teva
A US court yesterday ordered Teva Pharmaceutical Industries Ltd. to pay $235 million compensation to GlaxoSmithKline for violation of the latter's patent

GSK presented results of Benlysta drug study

gsk
GlaxoSmithKline announced results from study, which showed that Benlysta (belimumab) plus standard of care prolonged control of disease activity in patients with active systemic lupus erythematosus